Niaspan niacin: Additional Phase III data

The double-blind, North American Phase III AIM-HIGH trial in 3,414 patients showed that high doses of daily extended-release Niaspan plus Zocor simvastatin missed the primary endpoint of significantly reducing a composite of death from

Read the full 341 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE